多药耐药相关基因在胃癌的表达
- 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。
多药耐药相关基因在胃癌的表达
范开春;程留芳;樊代明;李春海;孙丽亚;王红丽
【期刊名称】《解放军医学杂志》
【年(卷),期】2001(026)001
【摘要】Multidrug resistance (MDR) is widely thought to be a major cause of the failure in cancer chemotherapy. The detection of MDR marker is therefore valuabe in studying the mechanisms of MDR and to predict response to chemotherapy in patient with carcinoma. Previous studies have examined MDR marker in gastric cancer, but the major part of the investigation in patients have focused on a single parameter. The purposes of this study were to detect the expression of glutathione S-transferase
pi(GST-π), multidrug resistance-associated protein(MRP), lung-resistance protein(LRP) and multidrug resistance gen 1 (MDR1) in the patients with primary gastric cancer, who had not received prior chemotherapy, and evaluate the correlation between GST-π, MRP, LRP and MDR1. The expression of GST-π, MRP, LRP and MDR1 mRNA in carcinoma tissue and the adjacent non-cancerous tissue from 50 patients was examined by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR). The positive rate of GST-π mRNA, MRP mRNA, LRP mRNA and MDR1 mRNA in gastric cancer tissue were 36.00%, 12.00%, 10.00%, and 10.00% respectively. Their expression in gastric cancer tissue was significantly higher than that in the adjacent non-cancerous tissue. The overall positive
rate of their expression in gastric tissue was 48.00%. The results indicated that GST-π mRNA, MRP mRNA, LRP mRNA and MDR1 mRNA are overexpressed in various degrees and no co-expression exists among the studied genes in gastric cancer,and perhaps intrinsic MDR exists in 46% patients with primary gastric cancer.%检测从未接受过化疗的胃癌病人胃癌组织及癌旁组织的酸性谷胱甘肽S-转移酶(GST-π)基因、多药耐药相关蛋白(MRP)基因、肺耐药蛋白(LRP)基因和多药耐药基因1(MDR1)。
使用半定量逆转录聚合链酶反应(RT-PCR)方法。
结果显示,在胃癌组织中,GST-π、MRP、LRP和MDR1表达阳性率分别为36.00%、12.00%、10.00%和10.00%,均显著高于癌旁组织中的表达,表达的总阳性率达46.00%。
说明上述4种基因在未化疗过的胃癌组织中均有不同程度的高表达;但它们之间无共表达。
近半数的胃癌病人可能存在固有性耐药。
【总页数】3页(P52-54)
【作者】范开春;程留芳;樊代明;李春海;孙丽亚;王红丽
【作者单位】解放军总医院;解放军总医院;第四军医大学西京医院;军事医学科学院基础医学研究所;军事医学科学院基础医学研究所;军事医学科学院基础医学研究所【正文语种】中文
【中图分类】R979.1
【相关文献】
1.胃癌细胞多药耐药相关基因的表达与其侵袭转移能力的相关性研究 [J], 李志海
2.胃癌多药耐药相关基因的研究现状 [J], 王晓瑾;江石湖;诸琦
3.胃癌多药耐药相关基因表达与胶滴肿瘤药物敏感的关系 [J], 韩旭;谭志军;姜伟
4.多药耐药相关基因在胃癌组织中的表达及意义 [J], 张威;邹寿椿;赵大健;姜蔚;赵仲生;徐文娟
5.多药耐药相关基因在胃癌中的表达及意义 [J], 刘建华;刘杜先
因版权原因,仅展示原文概要,查看原文内容请购买。